Concomitant variations of gastric tone and duodenal motility in humans: results of a placebo-controlled study assessing octreotide and sumatriptan.
OBJECTIVE
To describe the concomitant effects of octreotide and sumatriptan on fundic tone and duodenal phase III activity.


METHODS
A double-blind study was performed in nine volunteers, studied for 2 h after receiving 50 microg octreotide, 6 mg sumatriptan or placebo. Fundic tone variations were assessed by barostat while antroduodenal motility was studied concomitantly using manometry.


RESULTS
A rapid increase in intrabag volume was observed in all but one subject after both sumatriptan and octreotide administration, while only two subjects exhibited a volume variation after placebo, p<0.01. A significant decrease in the number of phasic contractions was observed after octreotide, while sumatriptan reduced only wave amplitudes (p<0.05). A total of 13 concomitant duodenal phase III-like activities were observed in the duodenum after octreotide, 3 after sumatriptan and 4 after placebo, all followed by spontaneous fundic relaxation with disappearance of phasic contractions, p<0.05. Spontaneous phase III activities were different from phases III-like activities after octreotide in velocity and duration (p<0.05).


CONCLUSIONS
Octreotide induced concomitant fundic relaxation, disappearance of phasic contractions and duodenal phase III-like activity. Sumatriptan relaxed the proximal stomach and reduced the amplitude of fundic phasic contractions without affecting concomitant antroduodenal phase III activity.
Savoye
Guillaume
G
Groupe Appareil Digestif Environnement Nutrition, Rouen University Hospital, France. g_savoye@hotmail.com
Bouin
Mickael
M
Labbé
Louis
L
Mosni
Grégory
G
Morcamp
Paola
P
Denis
Philippe
P
Ducrotté
Philippe
P
D000328:Adult; D004386:Duodenum / Q000187:drug effects / Q000502:physiology*; D005765:Gastrointestinal Agents / Q000494:pharmacology; D005769:Gastrointestinal Motility / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000494:pharmacology*; D010919:Placebos; D013270:Stomach / Q000187:drug effects / Q000502:physiology*; D018170:Sumatriptan / Q000494:pharmacology*
D005765:Gastrointestinal Agents; D010919:Placebos; D018170:Sumatriptan; D015282:Octreotide